In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activity ZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of
Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its BiTAC® platform Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:
First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology areas including click chemistry and conjugation technology.
VXA-222 advances into next phase at VERAXA ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful
ZURICH, SWITZERLAND, July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an Extraordinary General Meeting (EGM) today. All resolutions proposed by the Board of Directors and
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO), effective immediately.
Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial de-risking of the development path for this novel therapeutic modality ZURICH, SWITZERLAND – July
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in
